Welcome to our dedicated page for LAVA Therapeutics news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics stock.
LAVA Therapeutics N.V. reports developments as a clinical-stage immuno-oncology company built around its proprietary Gammabody® platform of bispecific gamma delta T cell engagers. Company news centers on programs for hematologic malignancies and solid tumors, including LAVA-1266 and partnered candidates JNJ-89853413 and PF-08046052.
Recurring updates also cover clinical and regulatory disclosures, partnership milestones, operating and financial results, restructuring actions, strategic-alternative reviews, material agreements, shareholder matters and corporate-status developments related to its common shares.
LAVA Therapeutics (NASDAQ: LVTX), a clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Stephen Hurly, will present in a fireside chat format on Monday, September 9, 2024, at 3:30 PM ET.
LAVA Therapeutics specializes in developing the proprietary Gammabody® platform of bispecific gamma delta T cell engagers. Investors and interested parties can access a webcast of the presentation through the company's website under the 'Events' tab in the investor relations section. The replay will be available for 90 days after the presentation.
LAVA Therapeutics announced its Q2 2024 financial results and business updates. Major highlights include progress in the Phase 1/2a trial of LAVA-1207 for mCRPC, currently at dose level 12, with the pembrolizumab combination arm initiated. The next data update for LAVA-1207 is expected in Q4 2024. LAVA has a strong balance sheet with $86.8 million in cash, supporting operations into mid-2026. Financially, revenue for Q2 2024 was zero, down from $5.1 million in Q2 2023. R&D expenses decreased to $6.3 million, and G&A expenses to $3.0 million. Net loss improved to $8.3 million from $12.7 million in Q2 2023. The company also plans to initiate the Phase 1 trial of LAVA-1266 by year-end 2024 in Australia and received a $7 million milestone payment from Pfizer in Q1 2024.
LAVA Therapeutics (NASDAQ: LVTX), a clinical-stage immuno-oncology company, announced its participation in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. The event will be held on June 25, 2024, at 9:30 AM ET. Stephen Hurly, President and CEO of LAVA, will present a fireside chat focusing on the company's proprietary Gammabody® platform of bispecific gamma delta T cell engagers. The presentation can be accessed via webcast under the 'Events' tab on LAVA Therapeutics' investor relations website and will be archived for 90 days post-presentation.
LAVA Therapeutics N.V. (NASDAQ: LVTX), a clinical-stage immuno-oncology company specializing in its Gammabody® platform, announced its annual general meeting of shareholders. The meeting is scheduled for Wednesday, June 19, 2024, at 2:00 pm CEST. Shareholders can find all relevant documents and information, including the notice and agenda, in the “Investors” section of LAVA's website and on the SEC's website. To attend, shareholders must register as outlined in the provided notice and agenda.
LAVA Therapeutics, a clinical-stage immuno-oncology company, will participate in the Jefferies Global Healthcare Conference. Stephen Hurly, President and CEO, will represent the company in a fireside chat on June 5, 2024, at 8:00 a.m. ET. The discussion will be available via webcast on the company's investor relations website. The webcast replay will be archived for 90 days following the event. LAVA focuses on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers.
LAVA Therapeutics provided updates and financial results for Q1 2024. Key developments include the ongoing Phase 1/2a trial of LAVA-1207 for prostate cancer, with a pembrolizumab combination expected in Q2 2024. LAVA received a $7 million milestone payment from Pfizer for PF-08046052 in Phase 1 trials. LAVA-1266 is on track for Q2 2024 IND submission. Financially, LAVA reported $7 million in revenue for Q1 2024, up from $1.2 million in Q1 2023, with cash reserves at $94.6 million, providing a runway into 2026. The net loss improved to $0.5 million from $13.9 million in Q1 2023, mainly due to reduced R&D and administrative expenses.
LAVA Therapeutics N.V. (NASDAQ: LVTX) will participate in the Citizens JMP Life Sciences Conference where Stephen Hurly, President and CEO, will join a fireside chat. The event will take place on May 13, 2024, at 10:00 a.m. ET. The webcast can be accessed on the investor relations section of the LAVA Therapeutics website.
Summary not available.
Summary not available.
Summary not available.